Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment

被引：0
|
作者：
Clémence Chevalier
Julie Dubourg
Sébastien Bolze
Pascale Fouqueray
机构：
[1] Poxel SA,
来源：
Clinical Pharmacokinetics | 2021年 / 60卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：485 / 490
页数：5
相关论文
共 50 条
  • [41] Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
    Kurata, Akifumi
    Yoshida, Takafumi
    Inoue, Megumi
    Ishizuka, Tomoko
    Nakatsu, Takafumi
    Shimizu, Takako
    Kato, Manabu
    Nishikawa, Yasuhiro
    Ishizuka, Hitoshi
    [J]. ADVANCES IN THERAPY, 2020, 37 (01) : 253 - 264
  • [42] Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid® IR) in subjects with moderate hepatic impairment
    Durnin, C
    Hind, ID
    Ghani, SP
    Yates, DB
    Molz, KH
    [J]. PROCEEDINGS OF THE WESTERN PHARMACOLOGY SOCIETY, 2001, 44 : 83 - 84
  • [43] Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
    Marcinak, John
    Vakilynejad, Majid
    Kogame, Akifumi
    Tagawa, Yoshihiko
    [J]. DRUGS IN R&D, 2018, 18 (02) : 109 - 118
  • [44] Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment
    Hossain, Mohammad
    Tiffany, Courtney
    Tao, Yu
    Barth, Aline
    Marbury, Thomas C.
    Preston, Richard A.
    Dumont, Etienne
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (06): : 588 - 597
  • [45] Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment
    Min, K. Chris
    Lasseter, Kenneth C.
    Marbury, Thomas C.
    Wrishko, Rebecca E.
    Hanley, William D.
    Wolford, Dennis G.
    de Haes, Joanna Udo
    Reitmann, Christina
    Gutstein, David E.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (09) : 746 - 752
  • [46] Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod
    Zhang, Peijin
    Hosein, Fareeda
    Yu, Kyungha
    Walker, Susan
    Syto, Mary
    Tirucherai, Giridhar
    Murthy, Bindu
    Tatosian, Daniel
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S843 - S843
  • [47] An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib
    Magee, Mindy He
    Shearn, Shawn
    Shaddinger, Bonnie
    Fang, Zixing
    Glaser, Ruchira
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (05) : 1014 - 1021
  • [48] Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
    Tortorici, Michael A.
    Toh, Melvin
    Rahavendran, S. V.
    LaBadie, Robert R.
    Alvey, Christine W.
    Marbury, Thomas
    Fuentes, Ernesto
    Green, Matthew
    Ni, Grace
    Hee, Brian
    Pithavala, Yazdi K.
    [J]. INVESTIGATIONAL NEW DRUGS, 2011, 29 (06) : 1370 - 1380
  • [49] Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
    Akce, Mehmet
    El-Khoueiry, Anthony
    Piha-Paul, Sarina A.
    Bacque, Emeline
    Pan, Peng
    Zhang, Zhi-Yi
    Ewesuedo, Reginald
    Gupta, Divya
    Tang, Yongqiang
    Milton, Ashley
    Zajic, Stefan
    Judson, Patricia L.
    O'Bryant, Cindy L.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (05) : 825 - 836
  • [50] Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment
    Almeida, Luis
    Potgieter, J. Hendrick
    Maia, Joana
    Potgieter, M. Alida
    Mota, Fernando
    Soares-da-Silva, P.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (03) : 267 - 273
12345